Microdosing onderzoek

This qualitative study (n=198) of opinions on microdosing found that they were generally well-tolerated and were used for therapeutic or enhancement purposes. The study analysed 32 videos and the self-report reactions to those videos.

This survey study (n=525) found that the motivation for microdosing (psilocybin and LSD) was mainly to improve mental health, personal development, and cognitive enhancement. Four out of five participants used one or more harm reduction techniques on microdosing days (e.g. not dosing when unwell, no alcohol, avoiding driving).

This prospective survey study (n=81) found that expectancy effects were mostly predictive of microdosing outcomes on reductions in state anxiety, depressive symptoms (at 4-week endpoint), and positive outcomes (e.g. psychological resilience, -connectedness, -flexibility).

This cross-sectional study (n=2,510) of US adults with psychedelic experience found that participants retrospectively reported widespread improvements in health behaviours including reduced alcohol (66%) and tobacco (49%) use, better dietary habits (49%), and decreased impulsivity (48-72%), with microdosers and frequent users showing greater positive changes.

These two randomised, double-blind, placebo-controlled trials (n=141) conducted in semi-naturalistic settings found that microdosing psilocybin truffles did not significantly affect cognitive control, memory, social cognition, subjective well-being, attention, mood, or self-reported cognitive flexibility compared to placebo. Initial effects in some domains did not remain significant after correcting for multiple comparisons.

This open-label Phase IIa trial (n=19, 15 male) found that an 8-week regimen of microdosed LSD (8μg initially, then 6-20μg twice weekly) for major depressive disorder was well-tolerated with no serious adverse events or cardiac valvulopathy, achieved 59.5% reduction in MADRS scores sustained for six months, and had only one withdrawal due to anxiety.

Analyzing brain activity through specific frequency bands reveals subtle shifts in brain organization that standard broad-spectrum analysis often misses.

Participants with major depressive disorder reported feeling more motivated, more connected to others, and better able to process emotions during an eight-week LSD microdosing trial.

Microdosing psilocybin can improve the quality of creative thinking by helping people come up with more original ideas.

Low doses of psilocybin may reduce the frequency of migraine attacks, but a two-dose “pulsed” schedule did not show a significant advantage over a single dose in this trial.